Taysha Gene Therapies (TSHA) Misses Q1 EPS by 24c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($1.31), $0.24 worse than the analyst estimate of ($1.07).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
• SanDisk stock target lifted by Citi on continued demand strength
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty